President Donald Trump, Pfizer CEO Albert Bourla and others on Sept. 30 announced a voluntary agreement involving TrumpRx, a new direct-to-consumer prescription drug platform. (Photo credit: White House video screenshot)
Direct-to-consumer drug platforms, like President Donald Trump’s new TrumpRx, could impact the cost of 340B prescription drugs by potentially affecting [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
